The brokerage projects synergies from its acquisition of RJ O'Brien to hit a $50M run rate as market volatility cools. StoneX Group expects cost synergies from its acquisition of RJ O'Brien to reach a $50M annual run rate by the end of Q1 fiscal 2027. The projection comes
The real estate investment trust raises its adjusted funds from operations outlook after targeting $120M in net investment for the period. FrontView REIT increased its Q2 2026 adjusted funds from operations per share guidance to a range of $1.32-$1.34. The revision follows
Occidental Petroleum commits to flat production and capital spending in 2027 while focusing on debt reduction. Occidental Petroleum will hold production and capital expenditures steady at $5.9 billion in 2027. The company aims to maintain this level while continuing debt-r
ACI Worldwide forecasts $1.895B-$1.925B revenue ACI Worldwide has raised its full-year revenue guidance to $1.895B-$1.925B. The company also raised its adjusted EBITDA outlook to $545M-$560M. In Q2 2026, ACI Worldwide reported 7% revenue growth and 12% adjusted E
Urban Edge reported Q2 FFO of $0.41, topping estimates by $0.04, as revenue rose 7.6% year-over-year to $122.78M. Urban Edge reported Q2 funds from operations of $0.41 per share, exceeding estimates by $0.04. Revenue reached $122.78M, up 7.6% year-over-year and $17.7M abov
NextCure's Q2 GAAP loss per share deepened to $2.80, missing estimates by $0.88 amid declining cash reserves. NextCure reported a Q2 GAAP loss of $2.80 per share, missing expectations by $0.88. The wider-than-anticipated loss reflects ongoing operational challenges for the
Somnigroup anticipates earnings per share of $2.85-$3.15 Somnigroup International Inc. reported net sales of $1.8 billion in Q2 2026. The company also reported adjusted EBITDA of $297 million. The earnings report comes as the company targets a leggett & platt clo
Phio reports $13.0 million in cash as of June 30, 2026, down from $21.0 million at year-end 2025, extending runway into late 2027. Phio Pharmaceuticals reported a Q2 GAAP loss of $0.36 per share, matching expectations. The company’s cash position declined to $13.0 million
The flooring manufacturer outlines cost-saving measures after reporting mid-single-digit order growth in Q3 2026. The Dixie Group announced a $17M profit improvement plan during its Q2 2026 earnings call, citing mid-single-digit higher orders for Q3. The initiative aims to
Cognition Therapeutics reports a smaller-than-expected Q2 loss, with cash reserves totaling $34.8 million as of June 30, 2026. Cognition Therapeutics posted a Q2 GAAP loss per share of $0.04, exceeding expectations by $0.02. The narrower loss reflects improved financial pe
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.